Skip to content
FIND A HEALTH VALLEY ACTOR

Horizon Europe for Swiss Researchers

Euresearch

Swiss entities can participate in most Horizon Europe calls. Funding is provided by the Swiss government as long as Switzerland is not associated to the programme.     The European programme for research and innovation, ‘Horizon Europe’, has a total of €95.5 billion with which to fund ground-breaking research that will impact society at all…

Read More

Tech4Eva selected 16 projects for its 2023 programme

Tech4Eva 2023

16 projects have been selected for the 2023 programme   Tech4Eva is an EPFL Innovation Park and Groupe Mutuel initiative that aims at creating a long-term impact for FemTech startups and a global FemTech Community. The 2023 international cohort was selected from a total of 147 applications from 40 countries. Since the start of the…

Read More

Debiopharm and Merck invest in artificial intelligence

Debiopharm Innovation Fund

Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, and M Ventures, the strategic, corporate venture capital arm of Merck, and Omnes Capital invested CHF 15.5 million in French startup Iktos     By 2025, one in two drugs is expected to be discovered and developed using artificial intelligence. Iktos is a French…

Read More

Oculis Announces US public listing on Nasdaq

Oculis

A Swiss Health Valley success story! Oculis goes public.   Oculis Holding AG (“Oculis”), based at EPFL Innovation Park in Lausanne, is a global biopharmaceutical company purposefully driven to save sight and improve eye care. On 3 March 2023, it announced its listing on Nasdaq after successfully closing the business combination between European Biotech Acquisition…

Read More

FluoSphera Secures a Pre-Seed Investment of $ 1M 

Fluosphera

The US accelerator IndieBio New York which is part of SOSV, Swiss-based Mountain Labs, and EFI Lake Geneva Ventures participated in this round along with private business angels.   Gregory Segala, CEO and co-founder of FluoSphera SA: “We express our deep gratitude to our investors who believe in the potential of our powerful in vitro…

Read More

Leenaards Foundation 2023 Science Prizes

Fondation Leenaards

Leenaards Foundation announces three winners of the 2023 Science Prizes. CHF 1.5 million are awarded to support biomedical research in the Swiss Health Valley   The Leenaards Foundation will hand out its annual Science Prize, together with over CHF 1.5 million in award money, to three research groups in the Lake Geneva region at a…

Read More

13 biotech companies to watch according to BioAlps and Labiotech.eu

13 Biotech to watch

BioAlps recently collaborated with Labiotech.eu to detect the 13 biotech and healthtech companies in the Swiss Health Valley to watch in 2023.     Adiposs Headquarters: Geneva Founded: 2020 Adiposs has developed ImageBAT, a first-in-class medical imaging product for brown adipose tissue.  Brown fat plays a central role in human metabolism and has a big…

Read More

Xsensio announces an agreement with Mayo Clinic

Xsensio

Xsensio Announces Know-How and Stock Purchase Agreement with Mayo Clinic   Xsensio, a Vaud-Based company that is developing the Lab-on-Skin© sensing platform, announced that it has entered into a know-how and stock purchase agreement with Mayo Clinic for the development of new wearable products based on short term health dynamics in critical care. Xsensio will…

Read More

FONGIT Innovation Fund

Send your application before 13 May 2026 for the FONGIT Innovation Fund (FIF) FONGIT, Fondation Genevoise pour l’Innovation Technologique, is the first innovation incubator in Switzerland, specialising in technological innovation in Geneva. The organisation currently supports more than 100 startups and projects in the fields of ICT, Engineering, and Life Sciences. It helps innovative projects…

Read More

Lonza invested CHF 1 billion in Visp in 2022

Ibex™ Lonza facilit in Visp Switzerland

The biopharmaceutical company employs 5,000 people in Valais, and also announced a 15% sales growth in 2022, representing a total of CHF 6.2 billion   Lonza has invested one billion francs in Visp (VS) and half a billion in Stein (AG) in 2022, according to the chairman of the group’s board of directors, Albert Baehni. Some…

Read More